What does CYTK stand for?
The stock ticker symbol CYTK represents shares of Cytokinetics, Incorporated, which is a publicly traded biopharmaceutical enterprise listed on the Nasdaq stock exchange. Cytokinetics focuses on discovering, developing, and commercializing novel small-molecule therapeutics that modulate muscle contractility, targeting serious cardiovascular and neuromuscular diseases such as hypertrophic cardiomyopathy and heart failure to improve patients' physical functioning and clinical outcomes.
Related FAQs
Diodes Incorporated records annual revenues scaling between USD 1.3 billion and USD 1.6 billion, positioning the company as a leading global manufacturer and supplier of high-quality discrete, analog, and semiconductor products.
Cytokinetics, Incorporated officially completed its initial public offering and began trading its common stock on the NASDAQ stock exchange under the ticker symbol CYTK on April 29, 2004.
Dacotah Bank is an established regional financial institution headquartered in Aberdeen, South Dakota, maintaining total consolidated assets exceeding $3.1 billion.
Construction firms operating under names matching D Construction represent regional engineering, heavy civil contracting, and commercial building enterprises holding multi-million-dollar asset valuations.
Cytokinetics is a specialty cardiovascular biopharmaceutical company focused on pioneering scientific innovations in muscle biology and developing potential new medicines for patients suffering from diseases of cardiac muscle dysfunction.
Cytokinetics is widely considered a promising player in the biotechnology sector, garnering strong positive sentiment from market analysts who view its future prospects favorably.
Cytokinetics, Incorporated (NASDAQ: CYTK) trades at $76.45 per share, supported by a robust market capitalization exceeding $10.3 billion.
Wall Street equity research analysts covering Cytokinetics, Incorporated (CYTK) establish a consensus 12-month average price target of approximately $99.37 to $105.00 per share.
Securities or corporate entities trading under ticker abbreviations similar to CELC are evaluated by financial professionals on a case-by-case basis depending on their specific industry sector, such as biotechnology or specialized technology.
Aficamten (marketed under brand names such as Myqorzo) has been authorized as a once-daily oral cardiac myosin inhibitor designed to treat symptomatic obstructive hypertrophic cardiomyopathy.
Yes, Dominion Energy (D) pays a quarterly dividend to its shareholders.
No, Cytokinetics (CYTK) does not pay dividends. As a growth-focused biotechnology company, it prioritizes the reinvestment of all available capital into its research, development, and commercialization efforts.
Assessing whether Celsius Holdings shares are undervalued requires analyzing standard valuation multiples—such as price-to-earnings and price-to-sales ratios—relative to its historical growth rates and projected future earnings.
Cytokinetics is a late-stage biopharmaceutical enterprise dedicated to discovering, developing, and commercializing muscle biology-directed medicines for treating serious cardiovascular and neuromuscular diseases.
The professional analyst consensus for Cytokinetics is a "Strong Buy," with virtually all covering analysts recommending that investors buy or hold the stock rather than sell.